Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
LAURUSLABS-ANSE
CIPLA-ANSE
DRREDDY-ANSE
MANKIND-ANSE
AUROPHARMA-ANSE
LUPIN-ANSE
SUDARSHAN-MNSE
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 12% | 9% |
| - | - | 45% | 39% |
| - | - | 67% | 36% |
| 13% | 13% | 12% | 13% |
Peer Comparison
Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
ZYDUSLIFE-A
LAURUSLABS-A
CIPLA-A
DRREDDY-A
MANKIND-A
AUROPHARMA-A
LUPIN-A
SUDARSHAN-M
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,748.9 | ₹424466 Cr | 35.09 | 12.07 | 62.82 | ₹11479 Cr |
| 9,029.85 | ₹246222 Cr | 84.18 | 34.04 | 128.41 | ₹2568 Cr |
| 4,594 | ₹176301 Cr | 80.83 | 16.72 | 97.06 | ₹2163 Cr |
| 1,124 | ₹112818 Cr | 25 | 9.42 | 62.53 | ₹5040 Cr |
| 2,036 | ₹110823 Cr | 101.36 | 6.8 | 29.25 | ₹889 Cr |
| 1,312.85 | ₹107447 Cr | 31.88 | 9.77 | 57.87 | ₹3879 Cr |
| 1,214.1 | ₹103471 Cr | 32.11 | 5.32 | 63.99 | ₹4196 Cr |
| 2,330.1 | ₹97850 Cr | 47.9 | 13.75 | 71.08 | ₹1913 Cr |
| 1,659.9 | ₹96836 Cr | 26.08 | 17.95 | 96.84 | ₹3505 Cr |
| 1,954.8 | ₹89629 Cr | 16.21 | 30.95 | 154.35 | ₹5333 Cr |
| 36.6 | ₹954 Cr | 37.95 | 0.23 | 1.16 | ₹23 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| ₹174 Cr | ₹221 Cr | ₹168 Cr | ₹169 Cr | ₹145 Cr | ₹162 Cr | ₹116 Cr | ₹129 Cr | ₹99 Cr |
| ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹84 L | ₹51 L | ₹32 L | ₹98 L |
| ₹176 Cr | ₹225 Cr | ₹170 Cr | ₹171 Cr | ₹146 Cr | ₹162 Cr | ₹116 Cr | ₹129 Cr | ₹100 Cr |
| ₹160 Cr | ₹202 Cr | ₹158 Cr | ₹161 Cr | ₹135 Cr | ₹146 Cr | ₹108 Cr | ₹116 Cr | ₹98 Cr |
| ₹17 Cr | ₹24 Cr | ₹12 Cr | ₹11 Cr | ₹12 Cr | ₹17 Cr | ₹8 Cr | ₹13 Cr | ₹3 Cr |
| ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| ₹8 Cr | ₹16 Cr | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹10 Cr | ₹4 Cr | ₹8 Cr | -₹2 Cr |
| ₹6 Cr | ₹11 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹7 Cr | ₹3 Cr | ₹6 Cr | -₹1 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| — | — | — | — | — |
| ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹10 Cr | ₹10 Cr |
| ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹104 Cr | ₹88 Cr | ₹77 Cr | ₹20 Cr | ₹13 Cr |
| ₹104 Cr | ₹88 Cr | ₹77 Cr | ₹20 Cr | ₹13 Cr |
| ₹131 Cr | ₹112 Cr | ₹101 Cr | ₹30 Cr | ₹23 Cr |
| ₹7,000 | ₹0 | ₹0 | ₹0 | ₹5 L |
| ₹10 Cr | ₹9 Cr | ₹12 Cr | ₹4 Cr | ₹3 Cr |
| ₹55 L | ₹1 Cr | ₹1 Cr | ₹86 L | ₹3 Cr |
| ₹29 L | ₹2 L | ₹18 L | ₹14 L | ₹14 L |
| ₹49 L | ₹42 L | ₹6 L | ₹4 L | ₹3 L |
| ₹11 Cr | ₹11 Cr | ₹13 Cr | ₹5 Cr | ₹5 Cr |
| — | — | — | — | — |
| ₹92 Cr | ₹57 Cr | ₹92 Cr | ₹74 Cr | ₹44 Cr |
| ₹6 Cr | ₹10 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr |
| ₹157 Cr | ₹91 Cr | ₹18 Cr | ₹24 Cr | ₹21 Cr |
| ₹5 Cr | ₹3 Cr | ₹71 L | ₹39 L | ₹28 L |
| ₹260 Cr | ₹160 Cr | ₹118 Cr | ₹103 Cr | ₹71 Cr |
| ₹402 Cr | ₹283 Cr | ₹232 Cr | ₹138 Cr | ₹99 Cr |
| ₹29 Cr | ₹40 L | ₹20 L | ₹19 L | ₹2 L |
| ₹171 Cr | ₹105 Cr | ₹34 Cr | ₹31 Cr | ₹30 Cr |
| — | — | — | — | — |
| ₹30 Cr | ₹29 Cr | ₹22 Cr | ₹8 Cr | ₹8 Cr |
| ₹6 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr |
| ₹24 Cr | ₹26 Cr | ₹20 Cr | ₹6 Cr | ₹6 Cr |
| ₹6 Cr | ₹2 Cr | ₹1 L | ₹54 L | ₹0 |
| ₹29 Cr | ₹12 Cr | ₹12 Cr | ₹22,000 | ₹22,000 |
| ₹29 Cr | ₹12 Cr | ₹12 Cr | ₹22,000 | ₹22,000 |
| ₹5 Cr | ₹2 Cr | ₹2 Cr | ₹94 L | ₹5 Cr |
| ₹4 Cr | ₹4 Cr | ₹0 | ₹0 | ₹0 |
| ₹68 Cr | ₹46 Cr | ₹34 Cr | ₹8 Cr | ₹12 Cr |
| — | — | — | — | — |
| ₹2 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 |
| ₹140 Cr | ₹86 Cr | ₹75 Cr | ₹47 Cr | ₹24 Cr |
| ₹160 Cr | ₹123 Cr | ₹82 Cr | ₹73 Cr | ₹60 Cr |
| ₹55 L | ₹14 L | ₹12 Cr | ₹24 L | ₹1 Cr |
| ₹3 Cr | ₹10 Cr | ₹1 Cr | ₹45 L | ₹43 L |
| ₹29 Cr | ₹18 Cr | ₹30 Cr | ₹9 Cr | ₹2 Cr |
| ₹335 Cr | ₹237 Cr | ₹199 Cr | ₹130 Cr | ₹88 Cr |
| ₹75 Cr | ₹77 Cr | ₹80 Cr | ₹27 Cr | ₹16 Cr |
| ₹402 Cr | ₹283 Cr | ₹232 Cr | ₹138 Cr | ₹99 Cr |
| ₹5 | ₹46 | ₹42 | ₹31 | ₹24 |
| ₹5 | ₹5 | ₹42 | ₹31 | ₹24 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| ₹22 Cr | ₹15 Cr | ₹9 Cr | ₹7 Cr | ₹4 Cr |
| ₹20 Cr | ₹9 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr |
| -₹3 Cr | -₹15 Cr | -₹42 Cr | -₹13 Cr | -₹4 Cr |
| ₹38 Cr | ₹10 Cr | -₹27 Cr | -₹2 Cr | ₹4 Cr |
| ₹35 Cr | ₹8 Cr | -₹29 Cr | -₹4 Cr | ₹3 Cr |
| -₹20 Cr | -₹7 Cr | -₹26 Cr | -₹1 Cr | -₹1 Cr |
| -₹14 Cr | -₹12 Cr | ₹66 Cr | ₹4 Cr | -₹1 Cr |
| ₹37 L | -₹12 Cr | ₹11 Cr | -₹1 Cr | -₹1 L |
| ₹14 L | ₹12 Cr | ₹24 L | ₹1 Cr | ₹1 Cr |
| ₹4 L | ₹15,000 | ₹0 | ₹0 | ₹0 |
| ₹55 L | ₹14 L | ₹12 Cr | ₹24 L | ₹1 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 6 out of 9 oscillators
RSI
43.81Sell
STOCH %K
40.46Neutral
MACD Level(12,26)
-0.47Sell
Ultimate Oscillator
48.32Sell
Aroon Oscillator
42.00Sell
BOP
-0.94Sell
CCI
-83.98Neutral
Williams %R
-59.54Neutral
Momentum
-3.38Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 7 out of 9 moving averages
EMA 9
37.49Sell
SMA 9
37.39Sell
EMA 21
38.01Sell
SMA 21
38.33Sell
EMA 50
38.11Sell
SMA 50
37.91Sell
EMA 200
34.25Buy
SMA 200
32.09Buy
WMA 20
37.74Sell
Pivot
Pivot
Classic
Resistance 5
42.45
Resistance 4
41.26
Resistance 3
40.07
Resistance 2
38.88
Resistance 1
38.17
Pivot
37.69
Support 1
36.98
Support 2
36.50
Support 3
35.31
Support 4
34.12
Support 5
32.93
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 58.93% | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% |
| 19.38% | 19.95% | 19.78% | 20.79% | 19.49% | 18.45% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 21.69% | 22.66% | 22.83% | 21.82% | 23.12% | 24.16% |
Bulk & block deals
Name
North Star Opportunities Fund Vcc-Bull Value Incorporated Vcc Sub-Fund
Setu Securities Pvt Ltd
Mansi Share & Stock Advisors Private Limited
Century India Opportunity Fund Pc
Saroj Gupta
Bishwanath Prasad Agrawal
Epitome Trading And Investments
Epitome Trading And Investments
Saroj Gupta
Epitome Trading And Investments
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 11 Feb 2025 | Purchase | 5.36 Cr | ₹35.73 | 15 L | Bulk | 0.623289 | BSE |
| 01 Jan 2025 | Purchase | 5.53 Cr | ₹44.35 | 12.48 L | Bulk | 0.518576 | BSE |
| 01 Jan 2025 | Sell | 5.53 Cr | ₹44.35 | 12.48 L | Bulk | 0.518576 | BSE |
| 28 Nov 2024 | Purchase | 6.72 Cr | ₹41.97 | 16 L | Bulk | 0.664841 | BSE |
| 25 Sep 2024 | Purchase | 6.18 Cr | ₹411 | 1.50 L | Bulk | 0.062495 | BSE |
| 25 Sep 2024 | Purchase | 5.74 Cr | ₹412.41 | 1.39 L | Bulk | 0.057841 | BSE |
| 25 Sep 2024 | Purchase | 5.70 Cr | ₹424.33 | 1.34 L | Bulk | 0.055847 | BSE |
| 25 Sep 2024 | Sell | 6.48 Cr | ₹421.92 | 1.54 L | Bulk | 0.063825 | BSE |
| 25 Sep 2024 | Sell | 3.19 Cr | ₹424.35 | 75.20 K | Bulk | 0.031248 | BSE |
| 23 Sep 2024 | Purchase | 4.69 Cr | ₹385.85 | 1.22 L | Bulk | 0.050528 | BSE |
Insider trading & SAST
Client name
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Sudarshan Pharma Industries Limited is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It outsource its manufacturing facility,
Corporate Actions
Date
Type
Details
Company details
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Sudarshan Pharma Industries Share Price
36.60-0.87 (-2.32%)
+33.09% past 1 Year
News
Sudarshan Pharma Industries incorporates wholly-owned subsidiary
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about disclosure
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about annual secretarial compliance report
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about newspaper advertisement
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about newspaper advertisement
Equity
SUDARSHAN
Sudarshan Pharma Ind reports Profit after tax of 9.54 Crores, in the March 2026 quarter
Equity
SUDARSHAN
Sudarshan Pharma Ind reports Profit after tax of 4.30 Crores, in the December 2025 quarter
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about compliance certificate
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about compliance certificate
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about press release
Equity
SUDARSHAN
Sudarshan Pharma Ind reports Profit after tax of 4.40 Crores, in the September 2025 quarter
Equity
SUDARSHAN
Sudarshan Pharma Industries invests Rs 25.50 crore to expand API manufacturing capacity
Equity
SUDARSHAN
Sudarshan Pharma Ind - Quaterly Results
Equity
SUDARSHAN
Sudarshan Pharma Ind reports Profit after tax of 3.73 Crores, in the June 2025 quarter
Equity
SUDARSHAN
Sudarshan Pharma Ind - Quaterly Results
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about trading window closure
Equity
SUDARSHAN
Sudarshan Pharma Industries gets nod to incorporate wholly-owned subsidiary in Canada
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about newspaper publication
Equity
SUDARSHAN
Sudarshan Pharma Industries informs about press release
Equity
SUDARSHAN
Sudarshan Pharma gains on getting nod to incorporate subsidiary in Poland
Equity
SUDARSHAN